In addition, both presence of IgA ACPA and IgA RF seems to have no additional value over concomitant IgG ACPA and IgM RF presence for the outcomes of ‘quick-attained and persistent’ remission, achievement of DFR and biological use in an early arthritis population with a treat-to-target approach. The gene discussed is CD79A; the disease is Arthritis.